期刊文献+

儿童神经母细胞瘤合并心力衰竭1例

A case of neuroblastoma complicated with heart failure in children
下载PDF
导出
摘要 报道1例儿童神经母细胞瘤合并心力衰竭并进行可能原因探讨。3岁7个月患儿,起病隐匿,以食欲减退为首发症状,完善腹部影像学及术后病理组织检查,确诊神经母细胞瘤。在近4个月的时间里,先后应用了“环磷酰胺”联合“伊立替康”,“依托泊苷”联合“顺铂”方案,“依托泊苷”联合“奈达铂”方案化疗。经过5个周期化疗后,患儿出现呼吸困难、强迫坐位、面色苍白、紫绀、烦躁等急性心力衰竭表现。对于神经母细胞瘤化疗后并发心力衰竭的报道,临床并不多见,应警惕并关注化疗药物对心脏的毒性作用,早期进行相关检查,改善心功能以改善预后。 One case of neuroblastoma complicated with heart failure in children is reported,and the possible cause was studied.The child patient is 3 years and 7 months old,the onset is occult and anorexia is the first symptom.After abdominal imaging and postoperative histopathological examination,it is diagnosed as neuroblastoma.In the 4 months of treatment,the following chemotherapy regimens have been used in turn:cyclophosphamide combined with irinotecan,etoposide combined with cisplatin,and then etoposide combined with nedaplatin.After 5 cycles of chemotherapy,the child has some symptoms of acute heart failure,including dyspnea,forced sitting position,pallor,cyanosis and irritation.Clinically there have been few reports on heart failure after chemotherapy for neuroblastoma,so we should be alert and pay attention to the toxic effect of chemotherapy medicines on heart,performing related examinations at an early stage in order to improve heart function and the prognosis.
作者 孟颖 MENG Ying(Department of Pediatrics,Shandong University of Traditional Chinese Medicine Affiliated Hospital Dongying Hospital(Dongying Hospital of Traditional Chinese Medicine),Dongying 257000,China)
出处 《中国中西医结合儿科学》 2023年第4期324-328,共5页 Chinese Pediatrics of Integrated Traditional and Western Medicine
关键词 神经母细胞瘤 化疗 心力衰竭 儿童 Neuroblastoma Chemotherapy Heart failure Children
  • 相关文献

参考文献9

二级参考文献58

  • 1Howlader N, Noone AM, Krapcho M, et al, eds. SEER statistics review, 1975-2009 ( Vintage 2009 Populations)[M]. Bethesda, Md: National Cancer Institute, 2012.
  • 2Homer M J, Ries LA, Krapcho M, et al. SEER cancer statistics review, 1975-2006[M]. Bethesda, Md: National Cancer Institute, 2009.
  • 3Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, andresponse to treatment[J]. J Clin Oncol, 1993, 11 (8): 1466- 1477.
  • 4Shimada H,Ambros IM, Dehner LP, et al. The Ivtemational Neuroblastoma Pathology Classification (the Shimada system) [J]. Cancer,1999,86 (2) : 364-372.
  • 5Peuchmaur M Amore ES, Joshi VV, et al. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular [J ]. Cancer, 2003, 98 (10) : 2274-2281.
  • 6Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report [J]. J Clin Oncol , 2009, 27 (2): 298-303.
  • 7Brisse HJ,McCarville MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project[D]. Radiology, 2011, 261 (1) : 243-257.
  • 8Brodeur GM,Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment[J]. J Clin Oncol, 1993,11 (8) : 1466- 1477.
  • 9Strother DR,London WB, Schmidt ML, et al. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641[J]. J Clin Oncol , 2012, 30 (15) : 1842-1848.
  • 10Baker DL, Schmidt ML, Cohn SL, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma[J]. N Engl J Med, 2010,363 (14): 1313-1323.

共引文献154

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部